Barry Labinger has been named executive vice president and president of Emergent BioSolutions Biosciences Division. He reports to Daniel J. Abdun-Nabi, Emergent’s president and chief executive officer. Mr. Labinger will be responsible for the strategic direction and management of the company’s biosciences division, including the development, manufacture, and commercialization of product candidates, partnering initiatives around biosciences programs and platform technologies MVAtor (modified vaccinia Ankara) and ADAPTIR (Modular Protein Technology), as well as the integration of future product acquisitions.
 
Mr. Labinger previously served as executive vice president and chief commercial officer at Human Genome Sciences. He has held a number of executive positions, including global head of 3M Pharmaceuticals, senior vice president and general manager commercial operations, and vice president, Enbrel marketing, at Immunex Corp. Mr. Labinger has also held a number of leadership positions in pharmaceutical marketing at Bristol-Myers Squibb and Abbott Laboratories.
 
“Barry brings to Emergent over two decades of extensive Biopharmaceutical experience that encompasses general management, commercialization, and business development — core competencies that are integral to achieving the goals we have set in our growth plan,” said Daniel J. Abdun-Nabi, Emergent’s president and chief executive officer. “As we look to expand our portfolio with specialized products that address the needs of hospitals and healthcare providers, Barry’s expertise will help greatly in establishing Emergent in the commercial marketplace.”